5 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Lennox Gastaut Syndrome: new trials by email Literature Review of Lennox Gastaut Syndrome trials Research Report on Lennox Gastaut Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1 / Phase 2 | Not yet recruiting | Alexander Rotenberg | 25 | 2025-01-01 | 2024-12-18 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 1 / Phase 2 | Completed | Longboard Pharmaceuticals | 52 | 2022-03-03 | 2024-11-08 |
| Bioavailability and Food Effect Study of 3 Types of Carisbamate Carisbamate - Healthy Subjects | Phase 1 | Completed | SK Life Science, Inc. | 33 | 2020-08-27 | 2021-10-07 |
| Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome Carisbamate - Lennox Gastaut Syndrome | Phase 1 | Completed | SK Life Science, Inc. | 15 | 2019-05-03 | 2024-04-04 |
| Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome Carisbamate - Lennox Gastaut Syndrome | Phase 1 | Completed | SK Life Science, Inc. | 18 | 2019-02-07 | 2023-05-30 |
| A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol ZX008 0.2 to 0.8 mg/kg/day, Cannabidiol - Dravet Syndrome, Lennox Gastaut Syndrome | Phase 1 | Completed | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 9 | 2018-01-19 | 2023-12-01 |
| Cannabidiol in Children With Refractory Epileptic Encephalopathy CanniMed® 1:20 - Epileptic Encephalopathy | Phase 1 | Unknown | University of Saskatchewan | 20 | 2017-04-26 | 2023-04-26 |
| The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy 12-Lead ECG, Cannabidiol - Lennox-Gastaut Syndrome, Dravet Syndrome | Phase 1 / Phase 2 | Terminated | Gillette Children's Specialty Healthcare | 2 | 2017-02-16 | 2022-08-30 |
Epilepsies, Myoclonic (5) · CDKL5 deficiency disorder (1) · Epilepsy (1) · Landau-Kleffner Syndrome (1) · Spasms, Infantile (1) · Tuberous Sclerosis (1)
Brain Diseases (8) · Central Nervous System Diseases (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Epileptic Syndromes (8) · Genetic Diseases, Inborn (8) · Nervous System Diseases (8) · Epilepsy (7) · Epilepsy, Generalized (5) · Congenital Abnormalities (1) · Hamartoma (1) · Heredodegenerative Disorders, Nervous System (1) · Malformations of Cortical Development (1) · Malformations of Cortical Development, Group I (1) · Neoplasms (1) · Neoplasms, Multiple Primary (1)
S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (3) · Cannabidiol (2) · Medical Marijuana (1)
SK Life Science, Inc. (3) · Alexander Rotenberg (1) · Gillette Children's Specialty Healthcare (1) · Longboard Pharmaceuticals (1) · University of Saskatchewan (1) · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (1)
United States (7) · Australia (1) · Canada (1)
Marc Kamin, MD (2) · Alexander Rotenberg, MD, PhD (1) · Beverly S Wical, MD (1) · Dennis J Dlugos, MD (1) · Jane Alcorn, PhD (1) · Richard Huntsman, MD (1) · Richard Tang-Wai, MD (1) · Ry R Forseth, Ph.D. (1)